SUMMARY Prostaglandin E1 (alprostadil, Prostin VR Sterile Solution, PGE1) was evaluated in patients with Raynaud's syndrome in a multiclinic, placebo-controlled, double-blind study. A total of 55 patients with either primary Raynaud's disease or Raynaud's disease secondary to systemic sclerosis were randomly assigned to receive either PGE, administered intravenously at 10 ng/kg/min for 72 hours or placebo administered in the same manner. The frequency and severity of Raynaud's attacks were then monitored for up to four weeks by use of in-clinic questionnaires and patients' daily diaries. Haemodynamic assessments included measurements of skin temperature and the finger systolic pressure response to localised digital cooling. Immediately after the infusion the overall symptoms in both the PGE1 and the placebo group showed marked improvement; by four weeks after infusion, in some cases, values had not returned to pretreatment levels. There was, however, no marked benefit of PGE, treatment over that of placebo. Although PGE, significantly increased skin temperature during and immediately after infusion, the effect did not persist at two-and four-week follow-up evaluations. The finger systolic pressure response to localised digital cooling (150C) increased more in the PGE,-treated group than in the placebo-treated group, but the difference was not statistically significant. There was no difference in ulcer healing between the two treatment groups. These results failed to substantiate earlier open-label reports that a 72-hour intravenous infusion of PGE, in patients with Raynaud's syndrome produced significant clinical benefit.
taglandin El (alprostadil, Prostin VR Sterile Solution, PGEI) can alleviate the symptoms associated with Raynaud's syndrome. Clifford et al.' reported on 26 patients with severe Raynaud's syndrome who were infused intravenously with PGE, (6-10 ng/kg/ min) for 72 hours. In 24 of these patients Raynaud's syndrome was secondary to other diseases. An overall subjective improvement was reported by 96% of the patients during PGE, infusion, by 81% two weeks later, and by 65% six weeks beyond the infusion period. At six weeks after infusion 63% (five out of eight patients) of ischaemic ulcers were healed. PGE, produced a decrease in the Dopplerderived pulsatility index, an increase in pulse volume recording amplitude, and an increase in skin temperature. However, PGE, had no effect on the skin temperature response to a standard challenge of hand immersion in cold water.
Pardy and coworkers2 3 also reported the openlabel use of intravenous PGE1 (10 ng/kg/min for 72 hours) to treat patients with Raynaud's disease.
They found that PGE, infusion reduced vasospasticity (as assessed by skin temperature) and increased the number of digital artery segments with Doppler-detectable flow. Moreover, PGE, decreased cold sensitivity, as shown by an increase in finger systolic pressure response to localised digital cooling. The beneficial effects extended for weeks beyond the infusion. Red cell flexibility, plasma fibrinogen, euglobulin lysis time, and antithrombin III were all increased after PGE1 treatment; blood viscosity, plasma ,-thromboglobulin, and platelet factor 4 were unchanged. Interestingly, symptomatic improvement (including ulcer healing) was only noted in those patients with ischaemic ulcers. Nearly all of these patients also underwent debridement, abscess drainage, and/or fingernail excision immediately after completion of PGE1 therapy. Thus the effect of PGE1 infusion alone, i.e., without the surgical procedures, remains uncertain.
The only placebo-controlled study which has been reported was that of Martin et The effect of PGE, on skin temperature did not persist at two and four weeks after infusion.
ULCERS
There were few ulcers in the study: 27 among 10 placebo patients and 13 among four PGE, patients. Three ulcers in placebo patients and one in a PGE, patient developed during the study. There was no difference between placebo and PGE, patients with respect to ulcer healing (26 and 23%, respectively).
FINGER SYSTOL IC PRESSURE
The finger systolic pressure (FSP) response to localised cooling (15°C) before and after treatment (Table 7) . Most of these occurred during infusion (55 with PGEI and 11 with placebo).
The 10 injection site problems occurred in six patients and were due in part to the use of a peripheral line in some of these patients. Although headache was equally prevalent in both treatment groups, more headaches during infusion were reported in PGE1 patients (nine) than in placebo patients (five). There were five severe events in the PGE, group and four in the placebo group. The severe events during infusion were peripheral oedema, headache, flushing, and inflammation and pain at the injection site. One of the four severe events in the placebo group was a death that occurred at the two-week follow up and was of cardiovascular origin. It was the only death reported throughout the study. The 'dy appreciable differences in laboratory abnormalities between PGE1 and placebo patients occurred immediately after infusion, at which time the PGE1 group had three to five more occurrences of (a) low values of serum albumin, red blood cells, haemoglobin, and prothrombin time and (b) high values of glucose, monocytes, and white blood cells.
Discussion
There have been several reports1-4 of clinical improvement in patients with Raynaud's disease after treatment with PGE, infusion. This improvement has been both subjective, such as a reduction in attack frequency and severity, and objective, such as changes in hand haemodynamic/rheological measurements and ulcer healing. The results of the present study do not agree with these reports, rather they show that a 72-hour infusion of PGE, does not provide a statistically significant clinical benefit over that of placebo treatment. Nevertheless, many of the parameters measured showed an appreciable improvement over pretreatment values in both placebo-and PGE1-treated patients. Thus this 'placebo effect' may account for the beneficial effect reported in a number of the earlier studies. Although the source of such improvement remains obscure, it may be that the hospitalisation of patients in a controlled environment for three days to administer PGE1 provides some degree of shortterm relief of symptoms. This is not to say that there is no therapeutic potential for PGE1 in the treatment of Raynaud's syndrome. In the present study PGE1 was given for only 72 hours. It may be that administration of PGE1 over a longer time period could provide a greater and more prolonged benefit. Also there was some reduction in the severity of Raynaud's symptoms after infusion of PGEI in the present study.
The coldness experienced immediately after infusion was somewhat less in PGE1 patients than in placebo patients. The severity of pain and stiffness in the hands was also less in PGE1-treated patients than in placebo patients at two and four weeks after infusion. The differences, however, were rarely statistically significant and were not clinically significant. (The PGEI-treated patients actually experienced more stiffness than placebo patients immediately after infusion. This is consistent with the vasodilatation and peripheral oedema that PGE, can produce.) Moreover, a significant increase was observed in skin temperature and finger systolic pressure to localised cooling during and immediately after infusion.
The results of the present study agree in part with some earlier reports that PGE, can increase skin temperature' 4 and decrease the vasospasm that results from localised digital cooling.2 The results do not, however, support the contention that a significant effect persists well beyond the infusion period.
Other methods of 'experimentally induced' vasospasm, such as hand immersion in cold water, also have failed to show an effect with PGE, in patients with Raynaud's disease. ' 4 There have been several reports of ulcer healing after PGE1 treatment.l This, too, was not substantiated in our study, though there were only a few ulcers in the study. Our obser-vation that ulcer healing can occur in placebo-treated patients may indicate that the healing observed in other studies may, again, have been due to a 'placebo effect'. In summary, in patients with Raynaud's syndrome, a 72-hour infusion of PGE1 failed to provide a more marked improvement than a 72-hour infusion of placebo. There was, however, a statistically significant improvement from preinfusion values in both placebo-and PGEI-treated patients.
